Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

Trial Profile

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms CoBRIM-B
  • Most Recent Events

    • 04 Apr 2016 According to ClinicalTrials.gov status changed from recruiting to discontinued due to slow accrual.
    • 23 Jun 2015 Status changed from not yet recruiting to recruiting, according to an abstract presented at 51st Annual Meeting of the American Society of Clinical Oncology
    • 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top